A preview of a partnership-driven biotech article about advancing a precision AAV9 gene therapy for SOD1-linked ALS into an institutional translational pipeline, highlighting collaborative development and next-stage plans.
Key Takeaways
- Institut Charcot, ARSLA, ReMedys Foundation and Avrion signed an MoU to develop AVR-001
- AVR-001 is an AAV9 gene therapy designed to reduce SOD1 production in motor neurons and astrocytes
- Substantial preclinical package shows SOD1 down-regulation, efficacy in SOD1 mouse models, and initial safety data